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To the Editor:
I read with great interest the report
by Sharma and colleagues1 about their
experience with aortic valve (AV)
repair and congratulate them on their
honest presentation of the long-term
data. I believe, however, that the
interpretation of some aspects needs
additional comments and questions.
The authors stated that survival after
AV repair in their population was
excellent and, with 91%, 80%, and
58% survival at 5, 10, and 15 years,
respectively, was indistinguishable
from the healthy population. Such a
survival of the healthy population
with a median age of 54 years seems
to be rather low, and this impression
could be intensified when looking at
the US Life Tables,2 which revealed
corresponding survival rates of 96%,368 The Journal of Thoracic and C90%, and 83% for a 54-year-old
population containing 76% men.
The authors found (not unexpectedly,
because this aspect has already been
revealed after AV replacement3) that
myocardial impairment (MI) was a
significant predictor of mortality.
They correctly noted that this is barely
avoidable, because the late presenta-
tion of symptoms in some patients
with aortic insufficiency does not
lead to referral for surgery until the
development of MI. They suggested,
however, earlier surgery for patients
with suitable repair anatomy. In this
context, 2 questions arise: how
reliable is the assessment of AV repair
suitability; and are patients with MI
proper candidates for AV repair? I
believe AV replacement should be
preferred for patients with consider-
able MI because such patients need a
fast and safe surgery without the risk
of residual or recurrent insufficiency,
let alone any intraoperative revisions.
The remaining aortic insufficiency,
which can never be ruled out after
repair, can even be considered as a
potential factor that can worsen long-
term survival in this special subgroup.
However, the authors did not provide
the rate of postoperative aortic insuffi-
ciency—neither in the entire nor in
this special cohort. Thus, I am
wondering whether the rate of reoper-
ation alone would be adequate enough
for assessment of clinical and, espe-
cially, functional results. Furthermore,
the number of patients operated at
Mayo Clinic, with an average of about
12 annually, does not indicate that a
considerable share of aortic valve
pathologic entities could be scheduled
for the repair. By coincidence, we
submitted an abstract for the same
American Association for Thoracic
Surgery meeting that included 137
repairs performed during a 1-year
period, but it was not well received
by the reviewers.
It seems that AV repairs are still
limited to single centers or, even, sur-
geons; hence, we can hardly speak
about the ‘‘expanding relevance ofardiovascular Surgery c July 2014AV repair.’’ The repair rate, as pre-
sented in our abstract, was 40% for
all AV surgery patients younger than
70 years or, after excluding patients
with contraindications (eg, MI), even
greater. Even if the suitability of repair
could be assessed with a probability of
about 80%, the final decision for AV
repair was always performed during
surgery. Thus, I am convinced that
AV repair is a valuable option; how-
ever, the repair candidates must fulfill
the same indication criteria as for AV
replacement,3 because the need for
replacement can never be ruled out.
Paul P. Urbanski, MD, PhD
Cardiovascular Clinic Bad Neustadt
Bad Neustadt, Germany
References
1. Sharma V, Suri RM, Dearani JA, Burkhart HM,
Park SJ, Joyce LD, et al. Expanding relevance of
aortic valve repair—is earlier operation indicated?
J Thorac Cardiovasc Surg. 2014;147:100-8.
2. Arias E, Curtin LR, Wei R, Anderson RN. US
decennial life tables for 1999-2001, United States
Life Tables. Natl Vital Stat Rep. 2008;58:1.
3. Bonow RO, Carabello BA, Chutturjee K, de
Leon AC Jr, Faxon DP, Freed MD, et al. 2008
Focused update incorporated into the ACC/AHA
2006 guidelines for the management of patients
with valvular heart disease: a report of the
American College of Cardiology/American Heart
Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2008;52:e1-142.
http://dx.doi.org/10.1016/
j.jtcvs.2014.02.041COX MAZE III PROCEDURE:
THE BEST ALTERNATIVE IN
SURGERY FOR ATRIAL
FIBRILLATION
To the Editor:
We read with particular attention
the article by Stulak and colleagues.1
After close scrutiny of this report
one cannot escape the conclusion
that standard cut-and-sew Cox maze
III procedure, as first described by
Cox and associates,2 remains the cri-
terion standard choice for the surgical
treatment of any type of atrial fibrilla-
tion (AF). Of special interest is the en-
tity of mitral valve (MV) disease with
concomitant long-standing persistent
Letters to the EditorAF. Unfortunately, alternative energy
sources used for the Cox maze IV
have not shown consistent results.3
We had the opportunity to compare 2
groups of patients who underwent
MV surgery and surgery for AF.
With regard to the AF, all the cases
were performed exclusively by the
cut-and-sew method to guarantee total
transmural lesions. One hundred pa-
tients underwent only isolation of the
pulmonary veins; 20 underwent a
Cox maze III procedure. All patients
were operated on by the same surgeon
(O.A.G.-V.). Sinus rhythm conversion
rate was immensely superior for the
Cox maze III group (19/20; 95%),
than for the pulmonary vein isolation
group (76/100; 76%) at 3 months’
follow-up. The prevalence of normal
sinus rhythm was higher in the Cox
maze III group at 6 months’ follow-
up (95% vs 54%). Although our
data have not yet been published, a
brief analysis of them shows that the
sole isolation of the pulmonary veins
is not enough to eliminate long-
standing persistent AF in the setting
of concomitant MV disease. In addi-
tion, the Cox maze III procedure
must be performed by the cut-and-
sew method, because this is the only
measure that will ensure transmural
lesions. Moreover, a biatrial lesion
set pattern is highly mandatory in the
Cox maze III procedure to eliminate
long-standing persistent AF.
Definitely, the standard cut-and-
sew Cox-maze III procedure remains
the best choice in surgery for AF,
especially for patients with MV
disease.
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To the Editor:
The noteworthy article by Singh
and coworkers,1 ‘‘Autophagy Gene
Fingerprint in Human Ischemia and
Reperfusion,’’1 recently published in
the Journal, illustrates the importance
of keeping surgeons informed about
potentially new approaches to treating
patients with heart disease. Although
the process of autophagy is well
known in the scientific community,
few cardiothoracic surgeons are aware
of its relevance to acquired heart
disease, general thoracic surgery, and
cardiothoracic transplantation.
This article brings to our attention
the accumulating evidence from
animal and human studies that cardiac
autophagy is an endogenous cellular
protective mechanism activated by
ischemic stress. Because ischemia-
reperfusion injury contributes to post-
operative morbidity and mortality in a
number of surgical settings, the pros-
pect of harnessing this pathway to
improve clinical outcome is highly
attractive. One obstacle to overcome
is the effective translation of preclini-
cal knowledge to clinical application.
The recent publication by Singh
and coworkers1 is a positive step
forward. These investigators conduc-
ted a comprehensive evaluation of
changes in expression of several
autophagy-related genes and upstream
regulators in 9 patients undergoing
coronary artery bypass grafting. Key
components of the autophagy pathwayof Thoracic and Cardiovascular Surgewere upregulated, including cysteine
protease Atg4 isoforms (Atg4A,
Atg4C, Atg4D), which contribute to
autophagosome formation by priming
LC3 for lipidation. The elevated
LC3II/LC3I ratio was interpreted as
an increase in cardiac autophagy.
Their conclusion, that cardiac auto-
phagy is induced in response to
ischemia/reperfusion, is consistent
with our 2013 observations2 in 19 pa-
tients undergoing heart surgery who
exhibited marked decreases in the
autophagy proteins p62/SQSTM1,
Beclin-1, Atg5-12, and LC3B. We
concluded that ischemia-reperfusion
injury was associated with a marked
acceleration in autophagic flux (clear-
ance). Of particular interest was the
decrease in p62, because this bifunc-
tional protein binds ubiquitinated tar-
gets and autophagosomal LC3. With
enhanced flux, the degradation of
autophagosomes and their cargo
increases, as reflected by depletion of
p62. We observed that decreases in
both LC3-I and LC3-II correlated
with a fall in p62 and that the magni-
tude of p62 depletion varied directly
with crossclamp time and inversely
with mortality and morbidity risk
scores. Why our findings with respect
to changes in LC3 and p62 differ
from those of Singh and coworkers1
is unclear, given our similar patient
demographics. One explanation could
lie with the differences in crossclamp
time (118 vs 78 minutes) and cardio-
pulmonary bypass time (145 vs 97
minutes); they were shorter in the
study of Singh and coworkers.1 The
key point is that both groups provide
translational information that supports
the concept that the homeostatic
intracellular repair response, or
adaptive autophagy, is active in
the human heart. This concept is
further supported byKassiotis and col-
leagues,3 who reported in 2009 that
left ventricular assist device
unloading of the failing human heart
was associated with a decrease in
autophagic activity, andGarcia and as-
sociates,4 who reported in 2012 thatry c Volume 148, Number 1 369
